brimonidine ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
alpha-2 adrenoreceptor agonists 395 59803-98-4

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • UK 14,304
  • mirvaso
  • brimonidine
  • brimonidine tartrate
  • bromoxidine
A quinoxaline derivative and ADRENERGIC ALHPA-2 RECEPTOR AGONIST that is used to manage INTRAOCULAR PRESSURE associated with OPEN-ANGLE GLAUCOMA and OCULAR HYPERTENSION.
  • Molecular weight: 292.14
  • Formula: C11H10BrN5
  • CLOGP: 1.49
  • LIPINSKI: 0
  • HAC: 5
  • HDO: 2
  • TPSA: 62.20
  • ALOGS: -3.28
  • ROTB: 1

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 1.50 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 10 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.01 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD

Approvals:

DateAgencyCompanyOrphan
March 25, 2020 PMDA Senju Pharmaceutical Co., Ltd
Sept. 6, 1996 FDA
Feb. 20, 2014 EMA GALDERMA INTERNATIONAL

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Treatment failure 477.58 17.46 332 9995 198711 63279984
Eye irritation 430.23 17.46 154 10173 21817 63456878
Ocular hyperaemia 417.26 17.46 156 10171 24988 63453707
Intraocular pressure increased 400.45 17.46 108 10219 5970 63472725
Eye pain 240.57 17.46 115 10212 33739 63444956
Corneal opacity 135.60 17.46 30 10297 713 63477982
Iridocyclitis 130.05 17.46 37 10290 2485 63476210
Vision blurred 122.91 17.46 109 10218 91815 63386880
Eye pruritus 110.38 17.46 56 10271 18615 63460080
Glaucoma 101.09 17.46 53 10274 18852 63459843
Visual acuity reduced 99.40 17.46 55 10272 21771 63456924
Inappropriate schedule of product administration 93.19 17.46 99 10228 103866 63374829
Dry eye 92.47 17.46 66 10261 40695 63438000
Corneal oedema 86.51 17.46 24 10303 1469 63477226
Foreign body sensation in eyes 85.43 17.46 26 10301 2208 63476487
Erythema of eyelid 84.84 17.46 26 10301 2260 63476435
Rebound effect 78.31 17.46 29 10298 4497 63474198
Erythema 78.27 17.46 118 10209 175633 63303062
Scleral hyperaemia 71.03 17.46 15 10312 284 63478411
Ocular surface disease 69.73 17.46 11 10316 33 63478662
Conjunctival hyperaemia 67.30 17.46 22 10305 2357 63476338
Uveitis 63.72 17.46 34 10293 12519 63466176
Eye swelling 59.51 17.46 41 10286 23877 63454818
Choroidal effusion 53.69 17.46 13 10314 463 63478232
Iris adhesions 52.94 17.46 12 10315 319 63478376
Hypotonia 52.40 17.46 27 10300 9258 63469437
Conjunctivitis allergic 49.37 17.46 14 10313 928 63477767
Eye discharge 47.32 17.46 22 10305 6041 63472654
Vitreous haemorrhage 46.28 17.46 16 10311 2034 63476661
Lacrimation increased 45.83 17.46 33 10294 20598 63458097
Dry mouth 44.55 17.46 59 10268 77804 63400891
Skin burning sensation 44.43 17.46 27 10300 12707 63465988
Visual impairment 43.79 17.46 61 10266 84385 63394310
Corneal deposits 43.35 17.46 10 10317 288 63478407
Intraocular pressure test abnormal 43.05 17.46 9 10318 162 63478533
Eye disorder 43.03 17.46 33 10294 22652 63456043
Eye inflammation 42.71 17.46 20 10307 5579 63473116
Blepharitis 41.84 17.46 16 10311 2709 63475986
Conjunctivitis 41.10 17.46 31 10296 20765 63457930
Meniscus injury 41.05 17.46 21 10306 7093 63471602
Hypersensitivity 40.68 17.46 122 10205 292563 63186132
Conjunctival scar 40.46 17.46 7 10320 42 63478653
Corneal neovascularisation 40.35 17.46 8 10319 109 63478586
Corneal disorder 40.34 17.46 14 10313 1800 63476895
Conjunctival follicles 40.10 17.46 6 10321 11 63478684
Cataract 36.98 17.46 46 10281 57007 63421688
Hypothermia 35.48 17.46 24 10303 13557 63465138
Product quality issue 35.39 17.46 36 10291 35829 63442866
Cystoid macular oedema 34.42 17.46 12 10315 1563 63477132
Visual field defect 33.94 17.46 18 10309 6543 63472152
Product container issue 32.90 17.46 12 10315 1781 63476914
Product delivery mechanism issue 31.14 17.46 8 10319 364 63478331
Eyelids pruritus 30.05 17.46 10 10317 1132 63477563
Photophobia 29.87 17.46 24 10303 17611 63461084
Abnormal sensation in eye 29.50 17.46 11 10316 1738 63476957
Product packaging quantity issue 28.35 17.46 10 10317 1349 63477346
Arthropathy 27.62 17.46 3 10324 234789 63243906
Blindness unilateral 26.42 17.46 15 10312 6226 63472469
Eyelid oedema 26.15 17.46 18 10309 10461 63468234
Maternal exposure during pregnancy 25.41 17.46 3 10324 220059 63258636
Bradycardia 24.16 17.46 43 10284 73184 63405511
Symblepharon 24.13 17.46 5 10322 86 63478609
Eyelid irritation 23.70 17.46 7 10320 536 63478159
Angle closure glaucoma 23.58 17.46 10 10317 2209 63476486
Open angle glaucoma 23.46 17.46 6 10321 268 63478427
Eye colour change 23.06 17.46 6 10321 287 63478408
Pain of skin 22.23 17.46 17 10310 11617 63467078
Accidental exposure to product by child 21.95 17.46 8 10319 1185 63477510
Corneal infiltrates 21.91 17.46 5 10322 137 63478558
Retinal detachment 21.71 17.46 13 10314 5956 63472739
Deep anterior chamber of the eye 21.09 17.46 3 10324 3 63478692
Macular oedema 21.08 17.46 11 10316 3866 63474829
Retinal vascular occlusion 20.82 17.46 6 10321 421 63478274
Intraocular pressure fluctuation 20.65 17.46 4 10323 48 63478647
Ocular discomfort 20.18 17.46 11 10316 4222 63474473
Flat anterior chamber of eye 20.07 17.46 4 10323 56 63478639
Eye haemorrhage 19.81 17.46 14 10313 8482 63470213
Eye operation 19.74 17.46 9 10318 2363 63476332
Vitreous floaters 19.16 17.46 12 10315 5954 63472741
Keratitis interstitial 18.78 17.46 3 10324 10 63478685
Retinopathy haemorrhagic 18.55 17.46 3 10324 11 63478684
Hepatic enzyme increased 18.53 17.46 5 10322 202323 63276372
Endocrine ophthalmopathy 18.15 17.46 6 10321 665 63478030
Joint swelling 18.11 17.46 16 10311 327650 63151045
Vitreous detachment 17.84 17.46 8 10319 2019 63476676
Infusion related reaction 17.57 17.46 9 10318 245512 63233183
Corneal scar 17.55 17.46 4 10323 109 63478586

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Treatment failure 537.41 18.80 233 6519 46464 34903715
Intraocular pressure increased 395.35 18.80 108 6644 5275 34944904
Ocular hyperaemia 242.61 18.80 89 6663 11363 34938816
Eye irritation 222.27 18.80 75 6677 7486 34942693
Corneal oedema 166.72 18.80 41 6711 1310 34948869
Eye pain 128.03 18.80 59 6693 13403 34936776
Visual acuity reduced 123.74 18.80 61 6691 16088 34934091
Ocular surface disease 123.36 18.80 20 6732 60 34950119
Choroidal detachment 112.57 18.80 24 6728 398 34949781
Corneal opacity 94.08 18.80 22 6730 564 34949615
Hypotony of eye 83.16 18.80 15 6737 97 34950082
Vision blurred 81.63 18.80 69 6683 45894 34904285
Eye pruritus 78.05 18.80 35 6717 7454 34942725
Foreign body sensation in eyes 76.99 18.80 19 6733 615 34949564
Blepharitis 70.05 18.80 21 6731 1424 34948755
Conjunctivitis 66.48 18.80 34 6718 9671 34940508
Iridocyclitis 63.11 18.80 20 6732 1632 34948547
Glaucoma 61.66 18.80 29 6723 6883 34943296
Corneal neovascularisation 59.44 18.80 10 6742 40 34950139
Punctate keratitis 49.15 18.80 12 6740 371 34949808
Conjunctival hyperaemia 48.34 18.80 18 6734 2384 34947795
Choroidal effusion 45.96 18.80 10 6742 183 34949996
Scleral hyperaemia 42.86 18.80 8 6744 64 34950115
Cataract 41.76 18.80 37 6715 26149 34924030
Lacrimation increased 39.43 18.80 23 6729 8459 34941720
Blindness 38.48 18.80 28 6724 14958 34935221
Retinal detachment 37.24 18.80 19 6733 5372 34944807
Eye discharge 36.62 18.80 14 6738 1992 34948187
Corneal infiltrates 36.44 18.80 8 6744 153 34950026
Product delivery mechanism issue 36.10 18.80 8 6744 160 34950019
Visual impairment 35.46 18.80 39 6713 35763 34914416
Hyperaemia 35.13 18.80 12 6740 1237 34948942
Erythema of eyelid 34.28 18.80 11 6741 934 34949245
Pyelitis 33.12 18.80 7 6745 111 34950068
Product container issue 32.91 18.80 10 6742 709 34949470
Dacryostenosis acquired 32.29 18.80 8 6744 263 34949916
Hypersensitivity 31.28 18.80 48 6704 60987 34889192
Cornea verticillata 31.03 18.80 6 6746 59 34950120
Corneal disorder 30.34 18.80 10 6742 924 34949255
Intraocular pressure decreased 30.34 18.80 6 6746 67 34950112
Conjunctival follicles 30.21 18.80 4 6748 0 34950179
Cystoid macular oedema 28.74 18.80 9 6743 706 34949473
Visual field defect 28.66 18.80 15 6737 4468 34945711
Conjunctivitis allergic 28.13 18.80 10 6742 1160 34949019
Dry eye 27.13 18.80 19 6733 9556 34940623
Anterior chamber inflammation 26.81 18.80 7 6745 285 34949894
Eye swelling 26.40 18.80 19 6733 9976 34940203
Thunderclap headache 26.23 18.80 6 6746 139 34950040
Hyphaema 26.17 18.80 8 6744 579 34949600
Visual acuity tests abnormal 25.88 18.80 5 6747 49 34950130
Keratic precipitates 25.65 18.80 6 6746 154 34950025
Open angle glaucoma 25.50 18.80 6 6746 158 34950021
Eyelids pruritus 25.04 18.80 6 6746 171 34950008
Ulcerative keratitis 24.33 18.80 10 6742 1719 34948460
Corneal deposits 23.64 18.80 6 6746 218 34949961
Keratitis interstitial 23.22 18.80 4 6748 19 34950160
Angle closure glaucoma 22.33 18.80 8 6744 949 34949230
Ocular discomfort 22.31 18.80 10 6742 2124 34948055
Corneal degeneration 21.11 18.80 4 6748 35 34950144
Giant papillary conjunctivitis 20.58 18.80 3 6749 3 34950176
Inappropriate schedule of product administration 20.14 18.80 40 6712 62256 34887923
Dermatitis exfoliative generalised 19.78 18.80 11 6741 3696 34946483
Reversible cerebral vasoconstriction syndrome 19.41 18.80 6 6746 451 34949728

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Intraocular pressure increased 579.75 16.20 156 12124 9049 79723059
Ocular hyperaemia 354.80 16.20 141 12139 28065 79704043
Eye irritation 315.60 16.20 119 12161 20562 79711546
Corneal oedema 235.67 16.20 59 12221 2561 79729547
Eye pain 205.52 16.20 105 12175 37473 79694635
Ocular surface disease 183.73 16.20 29 12251 94 79732014
Visual acuity reduced 171.81 16.20 86 12194 29383 79702725
Vision blurred 150.48 16.20 127 12153 105771 79626337
Blepharitis 107.06 16.20 33 12247 3091 79729017
Foreign body sensation in eyes 105.47 16.20 30 12250 2127 79729981
Choroidal detachment 97.24 16.20 22 12258 614 79731494
Conjunctival hyperaemia 91.99 16.20 32 12248 4381 79727727
Glaucoma 84.78 16.20 47 12233 19714 79712394
Erythema of eyelid 83.23 16.20 26 12254 2544 79729564
Eye pruritus 83.01 16.20 47 12233 20523 79711585
Corneal opacity 81.98 16.20 21 12259 999 79731109
Corneal neovascularisation 80.84 16.20 15 12265 149 79731959
Choroidal effusion 80.02 16.20 19 12261 658 79731450
Iridocyclitis 77.75 16.20 27 12253 3677 79728431
Erythema 77.65 16.20 130 12150 223160 79508948
Inappropriate schedule of product administration 74.22 16.20 97 12183 133531 79598577
Hypotony of eye 74.05 16.20 15 12265 243 79731865
Conjunctivitis allergic 71.12 16.20 21 12259 1699 79730409
Corneal deposits 69.54 16.20 16 12264 482 79731626
Iris adhesions 68.07 16.20 16 12264 530 79731578
Scleral hyperaemia 65.41 16.20 14 12266 300 79731808
Corneal disorder 65.18 16.20 21 12259 2270 79729838
Dry eye 64.46 16.20 50 12230 36881 79695227
Conjunctivitis 63.58 16.20 43 12237 25672 79706436
Conjunctival follicles 62.39 16.20 9 12271 12 79732096
Uveitis 56.15 16.20 34 12246 16796 79715312
Eye discharge 54.99 16.20 24 12256 6010 79726098
Cataract 54.39 16.20 57 12223 62063 79670045
Punctate keratitis 54.06 16.20 15 12265 971 79731137
Rebound effect 53.94 16.20 25 12255 7201 79724907
Retinal detachment 48.08 16.20 25 12255 9222 79722886
Cystoid macular oedema 47.68 16.20 16 12264 1964 79730144
Visual field defect 45.73 16.20 24 12256 9021 79723087
Vitreous haemorrhage 44.67 16.20 18 12262 3695 79728413
Corneal infiltrates 43.50 16.20 10 12270 300 79731808
Skin burning sensation 42.19 16.20 26 12254 13246 79718862
Anterior chamber inflammation 42.16 16.20 11 12269 563 79731545
Angle closure glaucoma 41.31 16.20 16 12264 2960 79729148
Eye inflammation 41.17 16.20 20 12260 6393 79725715
Lacrimation increased 40.46 16.20 31 12249 22446 79709662
Visual impairment 39.36 16.20 59 12221 92072 79640036
Blindness 38.12 16.20 33 12247 28350 79703758
Hypotonia 37.86 16.20 24 12256 12846 79719262
Eyelids pruritus 36.64 16.20 11 12269 942 79731166
Photophobia 36.26 16.20 28 12252 20500 79711608
Open angle glaucoma 34.93 16.20 9 12271 438 79731670
Ulcerative keratitis 34.68 16.20 15 12265 3674 79728434
Hyperaemia 33.74 16.20 14 12266 3096 79729012
Corneal scar 33.07 16.20 8 12272 300 79731808
Dacryostenosis acquired 33.05 16.20 9 12271 543 79731565
Eye disorder 33.02 16.20 28 12252 23384 79708724
Hyphaema 32.89 16.20 10 12270 894 79731214
Flat anterior chamber of eye 32.49 16.20 7 12273 155 79731953
Anterior chamber disorder 32.49 16.20 7 12273 155 79731953
Cornea verticillata 32.11 16.20 7 12273 164 79731944
Eye swelling 32.01 16.20 29 12251 26439 79705669
Keratic precipitates 31.77 16.20 8 12272 355 79731753
Dry mouth 31.53 16.20 52 12228 87967 79644141
Meniscus injury 31.51 16.20 17 12263 6751 79725357
Conjunctival scar 30.45 16.20 7 12273 210 79731898
Keratitis interstitial 30.11 16.20 5 12275 24 79732084
Abnormal sensation in eye 29.00 16.20 11 12269 1924 79730184
Retinal vascular occlusion 27.69 16.20 8 12272 599 79731509
Intraocular pressure test abnormal 27.67 16.20 6 12274 137 79731971
Pyelitis 27.26 16.20 7 12273 336 79731772
Eyelid oedema 27.12 16.20 20 12260 13667 79718441
Giant papillary conjunctivitis 27.07 16.20 4 12276 7 79732101
Trabeculectomy 26.56 16.20 5 12275 54 79732054
Bradycardia 26.44 16.20 62 12218 135495 79596613
Intraocular pressure decreased 26.23 16.20 6 12274 176 79731932
Intraocular pressure fluctuation 25.64 16.20 5 12275 66 79732042
Meibomian gland dysfunction 25.07 16.20 6 12274 215 79731893
Reaction to preservatives 24.50 16.20 6 12274 237 79731871
Dermatitis contact 23.86 16.20 17 12263 11016 79721092
Eyelid ptosis 23.85 16.20 17 12263 11027 79721081
Skin irritation 23.58 16.20 17 12263 11223 79720885
Macular oedema 23.41 16.20 13 12267 5461 79726647
Optic nerve cup/disc ratio increased 23.34 16.20 3 12277 0 79732108
Visual acuity tests abnormal 22.94 16.20 5 12275 117 79731991
Conjunctival oedema 22.61 16.20 8 12272 1150 79730958
Vitreous floaters 22.52 16.20 14 12266 7242 79724866
Corneal epithelium defect 22.14 16.20 7 12273 712 79731396
Dizziness 21.73 16.20 147 12133 526294 79205814
Thunderclap headache 21.46 16.20 6 12274 399 79731709
Blindness unilateral 21.03 16.20 14 12266 8132 79723976
Photopsia 21.00 16.20 12 12268 5324 79726784
Eyelid irritation 20.69 16.20 6 12274 455 79731653
Hypothermia 20.13 16.20 21 12259 22725 79709383
Deep anterior chamber of the eye 20.04 16.20 3 12277 6 79732102
Product quality issue 19.37 16.20 25 12255 33915 79698193
Keratopathy 18.66 16.20 7 12273 1187 79730921
Eyelid disorder 18.45 16.20 8 12272 1970 79730138
Accidental exposure to product by child 18.40 16.20 9 12271 2917 79729191
Prostaglandin analogue periorbitopathy 18.32 16.20 3 12277 13 79732095
Endocrine ophthalmopathy 17.99 16.20 6 12274 722 79731386
Corneal infection 17.99 16.20 4 12276 103 79732005
Pain of skin 17.64 16.20 16 12264 14597 79717511
Floppy iris syndrome 17.53 16.20 5 12275 358 79731750
Brain stem haematoma 17.18 16.20 4 12276 127 79731981
Corneal degeneration 16.89 16.20 4 12276 137 79731971
Panophthalmitis 16.41 16.20 4 12276 155 79731953
Iris atrophy 16.34 16.20 4 12276 158 79731950
Corneal epithelial microcysts 16.34 16.20 3 12277 28 79732080

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC D11AX21 DERMATOLOGICALS
OTHER DERMATOLOGICAL PREPARATIONS
OTHER DERMATOLOGICAL PREPARATIONS
Other dermatologicals
ATC S01EA05 SENSORY ORGANS
OPHTHALMOLOGICALS
ANTIGLAUCOMA PREPARATIONS AND MIOTICS
Sympathomimetics in glaucoma therapy
ATC S01GA07 SENSORY ORGANS
OPHTHALMOLOGICALS
DECONGESTANTS AND ANTIALLERGICS
Sympathomimetics used as decongestants
FDA MoA N0000000209 Adrenergic alpha-Agonists
FDA EPC N0000175552 alpha-Adrenergic Agonist
CHEBI has role CHEBI:35569 alpha-adrenergic agonists
CHEBI has role CHEBI:35674 antihypertensive drugs
CHEBI has role CHEBI:37886 adrenergic agonists
MeSH PA D018663 Adrenergic Agents
MeSH PA D000322 Adrenergic Agonists
MeSH PA D058647 Adrenergic alpha-2 Receptor Agonists
MeSH PA D000316 Adrenergic alpha-Agonists
MeSH PA D000959 Antihypertensive Agents
MeSH PA D002317 Cardiovascular Agents
MeSH PA D018377 Neurotransmitter Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Ocular hypertension indication 4210003 DOID:9282
Open-angle glaucoma indication 84494001 DOID:1067
Rosacea indication 398909004 DOID:8881
Bronchospasm contraindication 4386001
Complete atrioventricular block contraindication 27885002
Orthostatic hypotension contraindication 28651003
Acute cerebrovascular insufficiency contraindication 29322000
Hyperthyroidism contraindication 34486009 DOID:7998
Depressive disorder contraindication 35489007
Anaphylaxis contraindication 39579001
Sinus bradycardia contraindication 49710005
General anesthesia contraindication 50697003
Thromboangiitis obliterans contraindication 52403007 DOID:12918
Cerebrovascular disease contraindication 62914000 DOID:6713
Diabetes mellitus contraindication 73211009 DOID:9351
Pulmonary emphysema contraindication 87433001
Cardiogenic shock contraindication 89138009
Myasthenia gravis contraindication 91637004 DOID:437
Acute disease of cardiovascular system contraindication 128487001
Partial atrioventricular block contraindication 195039008
Decompensated cardiac failure contraindication 195111005
Hypoglycemic disorder contraindication 237630007
Raynaud's phenomenon contraindication 266261006
Pregnancy, function contraindication 289908002
Severe chronic obstructive pulmonary disease contraindication 313299006




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 7.64 Basic
pKa2 1.82 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
EQ 0.33% BASE MIRVASO GALDERMA LABS LP N204708 Aug. 23, 2013 RX GEL TOPICAL 8859551 May 25, 2024 TOPICAL TREATMENT OF FACIAL ERYTHEMA OF ROSACEA
EQ 0.33% BASE MIRVASO GALDERMA LABS LP N204708 Aug. 23, 2013 RX GEL TOPICAL 8410102 May 24, 2025 TOPICAL TREATMENT OF FACIAL ERYTHEMA OF ROSACEA
EQ 0.33% BASE MIRVASO GALDERMA LABS LP N204708 Aug. 23, 2013 RX GEL TOPICAL 8426410 May 24, 2025 TOPICAL TREATMENT OF FACIAL ERYTHEMA OF ROSACEA
EQ 0.33% BASE MIRVASO GALDERMA LABS LP N204708 Aug. 23, 2013 RX GEL TOPICAL 7439241 Aug. 25, 2025 TOPICAL TREATMENT OF FACIAL ERYTHEMA OF ROSACEA
0.025% LUMIFY BAUSCH AND LOMB INC N208144 Dec. 22, 2017 OTC SOLUTION/DROPS OPHTHALMIC 11596600 July 27, 2029 RELIEVES REDNESS OF THE EYE DUE TO MINOR EYE IRRITATIONS
0.025% LUMIFY BAUSCH AND LOMB INC N208144 Dec. 22, 2017 OTC SOLUTION/DROPS OPHTHALMIC 8293742 July 14, 2030 RELIEVES REDNESS OF THE EYE DUE TO MINOR EYE IRRITATIONS
0.025% LUMIFY BAUSCH AND LOMB INC N208144 Dec. 22, 2017 OTC SOLUTION/DROPS OPHTHALMIC 9259425 July 14, 2030 RELIEVES REDNESS OF THE EYE DUE TO MINOR EYE IRRITATIONS
EQ 0.33% BASE MIRVASO GALDERMA LABS LP N204708 Aug. 23, 2013 RX GEL TOPICAL 8513247 March 25, 2031 TOPICAL TREATMENT OF FACIAL ERYTHEMA OF ROSACEA
EQ 0.33% BASE MIRVASO GALDERMA LABS LP N204708 Aug. 23, 2013 RX GEL TOPICAL 8513249 March 25, 2031 TOPICAL TREATMENT OF FACIAL ERYTHEMA OF ROSACEA
EQ 0.33% BASE MIRVASO GALDERMA LABS LP N204708 Aug. 23, 2013 RX GEL TOPICAL 9861631 March 25, 2031 TOPICAL TREATMENT OF FACIAL ERYTHEMA OF ROSACEA
EQ 0.33% BASE MIRVASO GALDERMA LABS LP N204708 Aug. 23, 2013 RX GEL TOPICAL 9861632 March 25, 2031 TOPICAL TREATMENT OF FACIAL ERYTHEMA OF ROSACEA
EQ 0.33% BASE MIRVASO GALDERMA LABS LP N204708 Aug. 23, 2013 RX GEL TOPICAL 8053427 June 13, 2031 TOPICAL TREATMENT OF FACIAL ERYTHEMA OF ROSACEA

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Alpha-2C adrenergic receptor GPCR AGONIST EC50 8.47 WOMBAT-PK CHEMBL
Alpha-2A adrenergic receptor GPCR AGONIST EC50 8.39 WOMBAT-PK CHEMBL
Alpha-2B adrenergic receptor GPCR AGONIST EC50 7.26 WOMBAT-PK CHEMBL
Alpha-1B adrenergic receptor GPCR Ki 5.27 CHEMBL
Alpha-1A adrenergic receptor GPCR Ki 5.55 CHEMBL
5-hydroxytryptamine receptor 1A GPCR Ki 5.84 DRUG MATRIX
Alpha-1D adrenergic receptor GPCR Ki 6.07 DRUG MATRIX
Alpha-2B adrenergic receptor GPCR Ki 7.28 CHEMBL
5-hydroxytryptamine receptor 1A GPCR IC50 5.59 CHEMBL
Alpha-1A adrenergic receptor GPCR EC50 5.95 CHEMBL
Adrenergic receptor alpha-2 GPCR Ki 7.52 CHEMBL
Adrenergic receptor alpha-1 GPCR Ki 6.13 CHEMBL
Alpha-1B adrenergic receptor GPCR EC50 6.03 CHEMBL

External reference:

IDSource
E6GNX3HHTE UNII
D02076 KEGG_DRUG
70359-46-5 SECONDARY_CAS_RN
134615 RXNORM
C0525227 UMLSCUI
CHEBI:3175 CHEBI
J59 PDB_CHEM_ID
CHEMBL844 ChEMBL_ID
2435 PUBCHEM_CID
DB00484 DRUGBANK_ID
CHEMBL2062257 ChEMBL_ID
D000068438 MESH_DESCRIPTOR_UI
6863 INN_ID
520 IUPHAR_LIGAND_ID
14807 MMSL
205316 MMSL
240890 MMSL
31659 MMSL
4297 MMSL
44062 MMSL
46686 MMSL
108827001 SNOMEDCT_US
372547000 SNOMEDCT_US
386924004 SNOMEDCT_US
4021002 VANDF
4024043 VANDF
006196 NDDF
006197 NDDF

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
ALPHAGAN P HUMAN PRESCRIPTION DRUG LABEL 1 0023-9177 SOLUTION/ DROPS 1.50 mg OPHTHALMIC NDA 25 sections
ALPHAGAN P HUMAN PRESCRIPTION DRUG LABEL 1 0023-9177 SOLUTION/ DROPS 1.50 mg OPHTHALMIC NDA 25 sections
COMBIGAN HUMAN PRESCRIPTION DRUG LABEL 2 0023-9211 SOLUTION/ DROPS 2 mg OPHTHALMIC NDA 26 sections
COMBIGAN HUMAN PRESCRIPTION DRUG LABEL 2 0023-9211 SOLUTION/ DROPS 2 mg OPHTHALMIC NDA 26 sections
ALPHAGAN P HUMAN PRESCRIPTION DRUG LABEL 1 0023-9321 SOLUTION/ DROPS 1 mg OPHTHALMIC NDA 25 sections
ALPHAGAN P HUMAN PRESCRIPTION DRUG LABEL 1 0023-9321 SOLUTION/ DROPS 1 mg OPHTHALMIC NDA 25 sections
SIMBRINZA HUMAN PRESCRIPTION DRUG LABEL 2 0065-4147 SUSPENSION/ DROPS 2 mg OPHTHALMIC NDA 26 sections
SIMBRINZA HUMAN PRESCRIPTION DRUG LABEL 2 0065-4147 SUSPENSION/ DROPS 2 mg OPHTHALMIC NDA 26 sections
SIMBRINZA HUMAN PRESCRIPTION DRUG LABEL 2 0078-0904 SUSPENSION/ DROPS 2 mg OPHTHALMIC NDA 26 sections
SIMBRINZA HUMAN PRESCRIPTION DRUG LABEL 2 0078-0904 SUSPENSION/ DROPS 2 mg OPHTHALMIC NDA 26 sections
Mirvaso HUMAN PRESCRIPTION DRUG LABEL 1 0299-5980 GEL 5 mg TOPICAL NDA 26 sections
Mirvaso HUMAN PRESCRIPTION DRUG LABEL 1 0299-5980 GEL 5 mg TOPICAL NDA 26 sections
Brimonidine Tartrate/Timolol Maleate HUMAN PRESCRIPTION DRUG LABEL 2 0591-2422 SOLUTION/ DROPS 2 mg OPHTHALMIC ANDA 22 sections
Brimonidine Tartrate and Timolol Maleate HUMAN PRESCRIPTION DRUG LABEL 2 0781-7186 SOLUTION/ DROPS 2 mg OPHTHALMIC ANDA 23 sections
Brimonidine Tartrate and Timolol Maleate HUMAN PRESCRIPTION DRUG LABEL 2 0781-7186 SOLUTION/ DROPS 2 mg OPHTHALMIC ANDA 23 sections
Brimonidine Tartrate and Timolol Maleate HUMAN PRESCRIPTION DRUG LABEL 2 0832-1425 SOLUTION/ DROPS 2 mg OPHTHALMIC ANDA 27 sections
Brimonidine Tartrate Human Prescription Drug Label 1 14445-400 SOLUTION/ DROPS 2 mg OPHTHALMIC ANDA 24 sections
BRIMONIDINE TARTRATE HUMAN PRESCRIPTION DRUG LABEL 1 16590-883 SOLUTION/ DROPS 2 mg OPHTHALMIC ANDA 12 sections
Brimonidine HUMAN PRESCRIPTION DRUG LABEL 1 17478-715 SOLUTION/ DROPS 2 mg OPHTHALMIC ANDA 25 sections
Brimonidine HUMAN PRESCRIPTION DRUG LABEL 1 17478-715 SOLUTION/ DROPS 2 mg OPHTHALMIC ANDA 25 sections
Brimonidine Tartrate HUMAN PRESCRIPTION DRUG LABEL 1 24208-411 SOLUTION/ DROPS 2 mg OPHTHALMIC ANDA 22 sections
Brimonidine Tartrate HUMAN PRESCRIPTION DRUG LABEL 1 24208-411 SOLUTION/ DROPS 2 mg OPHTHALMIC ANDA 22 sections
Brimonidine Tartrate HUMAN PRESCRIPTION DRUG LABEL 1 24208-411 SOLUTION/ DROPS 2 mg OPHTHALMIC ANDA 22 sections
LUMIFY Redness Reliever Eye Drops HUMAN OTC DRUG LABEL 1 24208-537 SOLUTION/ DROPS 0.25 mg OPHTHALMIC NDA 13 sections
LUMIFY Redness Reliever Eye Drops HUMAN OTC DRUG LABEL 1 24208-537 SOLUTION/ DROPS 0.25 mg OPHTHALMIC NDA 13 sections
LUMIFY Redness Reliever Eye Drops HUMAN OTC DRUG LABEL 1 24208-537 SOLUTION/ DROPS 0.25 mg OPHTHALMIC NDA 13 sections
LUMIFY Redness Reliever Eye Drops HUMAN OTC DRUG LABEL 1 24208-537 SOLUTION/ DROPS 0.25 mg OPHTHALMIC NDA 13 sections
Brimonidine Tartrate HUMAN PRESCRIPTION DRUG LABEL 1 25685-715 SOLUTION/ DROPS 2 mg OPHTHALMIC ANDA 12 sections
BRIMONIDINE HUMAN PRESCRIPTION DRUG LABEL 1 45802-078 GEL 5 mg TOPICAL ANDA 26 sections
Brimonidine Tartrate ophthalmic solution, 0.15% Human Prescription Drug Label 1 46708-661 SOLUTION/ DROPS 1.50 mg OPHTHALMIC ANDA 24 sections